News

Explore

NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

09.06.2021

NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma

20.05.2021

NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

07.04.2021

NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials

22.02.2021

NovalGen announces updates to its executive management team

19.02.2021

Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies

06.10.2020

Media Coverage

Published in the March 2021 edition of MedNous, a publication of Evernow Publishing Ltd.

Read more